Mbx Biosciences Common Stock Performance
| MBX Stock | 30.54 2.43 7.37% |
The firm secures a Beta (Market Risk) of -0.0104, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning MBX Biosciences are expected to decrease at a much lower rate. During the bear market, MBX Biosciences is likely to outperform the market. At this point, MBX Biosciences Common has a negative expected return of -0.0025%. Please make sure to verify MBX Biosciences' semi variance, as well as the relationship between the daily balance of power and period momentum indicator , to decide if MBX Biosciences Common performance from the past will be repeated at future time.
Risk-Adjusted Performance
Weak
Weak | Strong |
Over the last 90 days MBX Biosciences Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong fundamental drivers, MBX Biosciences is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 1.29 | Five Day Return (11.58) | Year To Date Return 7.92 | Ten Year Return 39.41 | All Time Return 39.41 |
1 | MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 | 12/15/2025 |
2 | A Look at MBX Biosciences Valuation After Goldman Sachs Bearish Initiation of Coverage | 12/19/2025 |
3 | Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday | 01/07/2026 |
4 | Insider Trading | 01/20/2026 |
5 | MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair | 01/22/2026 |
6 | Acquisition by Hawryluk P. Kent of 164500 shares of MBX Biosciences at .07 subject to Rule 16b-3 | 02/02/2026 |
7 | Acquisition by Salomon Azoulay of 70000 shares of MBX Biosciences at .07 subject to Rule 16b-3 | 02/03/2026 |
8 | MARBLEX Price Reaches 0.0591 | 02/05/2026 |
9 | MBX Biosciences Trading 8.5 percent Higher Heres Why | 02/12/2026 |
10 | Evaluating MBX Biosciences Valuation After MBX 2109 Phase 2 Progress And Stronger Investor Sentiment | 02/24/2026 |
| Begin Period Cash Flow | 30.5 M | |
| Total Cashflows From Investing Activities | -160.6 M |
MBX Biosciences Relative Risk vs. Return Landscape
If you would invest 3,394 in MBX Biosciences Common on December 3, 2025 and sell it today you would lose (340.00) from holding MBX Biosciences Common or give up 10.02% of portfolio value over 90 days. MBX Biosciences Common is generating negative expected returns assuming volatility of 5.9727% on return distribution over 90 days investment horizon. In other words, 53% of stocks are less volatile than MBX, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
MBX Biosciences Target Price Odds to finish over Current Price
The tendency of MBX Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 30.54 | 90 days | 30.54 | about 82.98 |
Based on a normal probability distribution, the odds of MBX Biosciences to move above the current price in 90 days from now is about 82.98 (This MBX Biosciences Common probability density function shows the probability of MBX Stock to fall within a particular range of prices over 90 days) .
MBX Biosciences Price Density |
| Price |
Predictive Modules for MBX Biosciences
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as MBX Biosciences Common. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.MBX Biosciences Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. MBX Biosciences is not an exception. The market had few large corrections towards the MBX Biosciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold MBX Biosciences Common, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of MBX Biosciences within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.23 | |
β | Beta against Dow Jones | -0.01 | |
σ | Overall volatility | 4.08 | |
Ir | Information ratio | 0.03 |
MBX Biosciences Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of MBX Biosciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for MBX Biosciences Common can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| MBX Biosciences generated a negative expected return over the last 90 days | |
| MBX Biosciences has high historical volatility and very poor performance | |
| MBX Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| Reported Net Loss for the year was (61.92 M) with profit before taxes, overhead, and interest of 0. | |
| MBX Biosciences generates negative cash flow from operations | |
| MBX Biosciences has a frail financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Evaluating MBX Biosciences Valuation After MBX 2109 Phase 2 Progress And Stronger Investor Sentiment |
MBX Biosciences Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of MBX Stock often depends not only on the future outlook of the current and potential MBX Biosciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. MBX Biosciences' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 33.4 M | |
| Cash And Short Term Investments | 262.1 M |
MBX Biosciences Fundamentals Growth
MBX Stock prices reflect investors' perceptions of the future prospects and financial health of MBX Biosciences, and MBX Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on MBX Stock performance.
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.17 | ||||
| Current Valuation | 1.07 B | ||||
| Shares Outstanding | 44.9 M | ||||
| Price To Book | 3.77 X | ||||
| EBITDA | (67.95 M) | ||||
| Net Income | (61.92 M) | ||||
| Total Debt | 171 K | ||||
| Book Value Per Share | 8.67 X | ||||
| Cash Flow From Operations | (54.68 M) | ||||
| Earnings Per Share | 7.67 X | ||||
| Market Capitalization | 1.46 B | ||||
| Total Asset | 268.54 M | ||||
| Retained Earnings | (137.5 M) | ||||
| Working Capital | 256.24 M | ||||
About MBX Biosciences Performance
Evaluating MBX Biosciences' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if MBX Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if MBX Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.21) | (0.22) | |
| Return On Capital Employed | (0.24) | (0.25) | |
| Return On Assets | (0.21) | (0.22) | |
| Return On Equity | (0.28) | (0.26) |
Things to note about MBX Biosciences Common performance evaluation
Checking the ongoing alerts about MBX Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for MBX Biosciences Common help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| MBX Biosciences generated a negative expected return over the last 90 days | |
| MBX Biosciences has high historical volatility and very poor performance | |
| MBX Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| Reported Net Loss for the year was (61.92 M) with profit before taxes, overhead, and interest of 0. | |
| MBX Biosciences generates negative cash flow from operations | |
| MBX Biosciences has a frail financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Evaluating MBX Biosciences Valuation After MBX 2109 Phase 2 Progress And Stronger Investor Sentiment |
- Analyzing MBX Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MBX Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining MBX Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating MBX Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of MBX Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of MBX Biosciences' stock. These opinions can provide insight into MBX Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for MBX Stock Analysis
When running MBX Biosciences' price analysis, check to measure MBX Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MBX Biosciences is operating at the current time. Most of MBX Biosciences' value examination focuses on studying past and present price action to predict the probability of MBX Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MBX Biosciences' price. Additionally, you may evaluate how the addition of MBX Biosciences to your portfolios can decrease your overall portfolio volatility.